4.2. Chemotherapy of malignant pleural mesothelioma;4.2. Chimiothérapie du mésothéliome pleural malin

Revue des Maladies Respiratoires

Volumn 23, Issue 4 C3, 2006, Pages

  Berghmans, T ^a   Brechot J M ^b   Robinet, G ^c   Guigay, J ^d   Morere P ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b AVICENNE HOSPITAL   (France)

^c CHU MORVAN   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZACITIDINE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; EDATREXATE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMIDAZOLECARBOXAMIDE; INTERFERON; INTERFERON ALPHA2B; IRINOTECAN; MENOGARIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PEMETREXED; PIRARUBICIN; RALTITREXED; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; NOTE; PLEURA MESOTHELIOMA; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; MESOTHELIOMA; PLEURA TUMOR;

HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 33847039557     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(06)71786-7     Document Type: Note

References (137)

1. Gehan EA : The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961 ; 13 : 346-53.
2. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C et coll. : Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002 ; 38 : 111-21.
3. Berghmans T, Lafitte JJ, Mascaux C, Meert AP, Paesmans M, Sculier JP : Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Cancer Therapy 1 2003 : 245-56.
4. Muers MF, Rudd RM, O'Brien ME, Qian W, Hodson A, Parmar MK et coll. : BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 2004 ; 59 : 144-8.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et coll. : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 ; 21 : 2636-44.
6. van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, vanMarck EA, Vincent M et coll. : Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005 ; 23 : 6881-9.
7. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C et coll. : Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005 ; 16 : 923-7.
8. Giaccone G, O'Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B : Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002 ; 38 Suppl 8 : S19-S24.
9. Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF : Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984 ; 54 : 961-4.
10. Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A et coll. : Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005 ; 48 : 429-34.
11. Sorensen PG, Bach F, Bork E, Hansen HH : Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985 ; 69 : 1431-2.
12. DeVita VT Jr : The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983 ; 51 : 1209-20.
13. Skipper HE, Schabel FM Jr., Wilcox WS : Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964 ; 35 : 1-111.
14. Skipper HE : Laboratory models: some historical perspective. Cancer Treat Rep 1986 ; 70 : 3-7.
15. O'Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A et coll. : A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006 ; 17 : 270-5.
16. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N : Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005 ; 48 : 291-6.
17. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L et coll. : A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2005 ; 16S : 625.
18. Govindan R, Kratzke RA, Herndon JE, Niehans GA, Vollmer R, Watson D et coll. : Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005 ; 11 : 2300-4.
19. Mathy A, Baas P, Dalesio O, Zandwijk NV : Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial. Lung Cancer 2005 ; 50 : 83-6.
20. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K et coll. : Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc ASCO 2003 ; 22 : 228.
21. Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL : A phase II trial of imatinib mesylate in patients with malignant mesothelioma. Proc ASCO 2004 ; 23 : 663.
22. Mazumdar M, Smith A, Schwartz LH : A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004 ; 57 : 358-65.
23. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, van Meerbeeck JP : Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004 ; 43 : 63-9.
24. Byrne MJ, Nowak AK : Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004 ; 15 : 257-60.
25. Nowak AK : CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005 ; 49 Suppl 1: S37-S40.
26. Byrne M, Francis R, van des Schaaf A, Boucek J, Price R, Patrikeos A et coll. : Comparison of FDG-PET and CT scans to assess response to chemotherapy in patients with malignant mesothelioma. Lung Cancer 2005 ; 49 : S27.
27. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et coll. : Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999 ; 35 : 1773-82.
28. Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ : Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 2006 ; 14 : 11-21.
29. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C et coll. : Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993 ; 11 : 1559-65.
30. Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M et coll. : Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987 ; 5 : 86-91.
31. Planting AS, Schellens JH, Goey SH, van der Burg ME, Boer-Dennert M, Stoter G et coll. : Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994 ; 5 : 373-4.
32. Markman M, Cleary S, Pfeifle C, Howell SB : Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986 ; 58 : 18-21.
33. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L : A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988 ; 6 : 223-6.
34. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R : Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985 ; 69 : 711-2.
35. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR et coll. : Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005 ; 23 : 3495-501.
36. Planting AS, van der Burg ME, Goey SH, Schellens JH, van den Bent MJ, Boer-Dennert M et coll. : Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995 ; 6 : 613-5.
37. Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K : A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 1988 ; 6 : 327-9.
38. Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D et coll. : Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994 ; 11 : 299-303.
39. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K et coll. : Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998 ; 9 : 269-73.
40. Kasseyet S, Astoul P, Boutin C. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer 1999 ; 85 : 1740-9.
41. Metintas M, Ozdemir N, Ucgun I, Elbek O, Kolsuz M, Mutlu S et coll. : Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 1999 ; 116 : 391-8.
42. Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Heeren T et coll. : Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994 ; 51 : 348-51.
43. Hasturk S, Tastepe I, Unlu M, Cetin G, Baris YI : Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996 ; 8 : 159-64.
44. Pass HW, Temeck BK, Kranda K, Steinberg SM, Pass HI : A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 1995 ; 2 : 214-20.
45. Trandafir L, Ruffié P, Borel C, Monnet I, Soulie P, Adams D et coll. : Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997 ; 33 : 1900-2.
46. Purohit A, Moreau L, Dietemann A, Seibert R, Pauli G, Wihlm JM et coll. : Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 1998 ; 22 : 119-125.
47. Soulie P, Ruffie P, Trandafir L, Monnet I, Tardivon A, Terrier P et coll. : Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996 ; 14 : 878-85.
48. Samuels BL, Herndon JE, Harmon DC, Carey R, Aisner J, Corson JM et coll. : Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998 ; 82 : 1578-84.
49. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M et coll. : Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999 ; 17 : 25-30.
50. van Haarst JM, Baas P, Manegold C, Schouwink JH, Burgers JA, de Bruin HG et coll. : Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002 ; 86 : 342-5.
51. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D et coll. : A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002 ; 87 : 491-6.
52. Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G et coll. : Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005 ; 28 : 223-6.
53. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M et coll. : Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999 ; 85 : 2375-84.
54. Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A et coll. : Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 1997 ; 79 : 1897-902.
55. Breau JL, Boaziz C, Morère JF, et coll. : Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III pleural mesothelioma. Eur Respir Rev 1993 ; 3 : 223-5.
56. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G et coll. : Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995 ; 76 : 2230-6.
57. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J : Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988 ; 11 : 118-20.
58. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M et coll. : Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991 ; 67 : 2984-7.
59. Parra HS, Tixi L, Latteri F, Bretti S, Alloisio M, Gravina A et coll. : Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001 ; 92 : 650-6.
60. Berghmans T, Lafitte JJ, Paesmans M, Stach B, Berchier MC, Wackenier P et coll. : A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma. Lung Cancer 2005 ; 50 : 75-82.
61. Mbidde EK, Harland SJ, Calvert AH, Smith IE. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986 ; 18 : 284-5.
62. Cantwell BM, Franks CR, Harris AL. A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 1986 ; 18 : 286-8.
63. Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P et coll. : Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990 ; 8 : 151-4.
64. Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J et coll. : Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990 ; 27 : 239-42.
65. Favaretto AG, Aversa SM, Paccagnella A, Manzini VP, Palmisano V, Oniga F et coll. : Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003 ; 97 : 2791-7.
66. O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP : A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999 ; 17 : 195-200.
67. Bakhshandeh A, Bruns I, Traynor A, Robins HI, Eberhardt K, Demedts A et coll. : Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma. Lung Cancer 2003 ; 39 : 339-45.
68. Fizazi K, Doubre H, Le Chevalier T, Riviere A, Viala J, Daniel C et coll. : Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003 ; 21 : 349-54.
69. Maisano R, Caristi N, Toscano G, Aragona M, Spadaro P, Amadio P et coll. : Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study. Tumori 2001 ; 87 : 391-3.
70. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B et coll. : A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003 ; 4 : 294-7.
71. Fennell DA, JP CS, Shamash J, Sheaff MT, Evans MT, Goonewardene TI et coll. : Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005 ; 47 : 277-81.
72. Upham JW, Musk AW, van Hazel G, Byrne M, Robinson BW: Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993 ; 23 : 683-7.
73. Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E et coll. : A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994 ; 5 : 653-5.
74. Carmichael J, Cantwell BM, Harris AL : A phase II trial of ifosfamide/ mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 1989 ; 25 : 911-2.
75. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S et coll. : Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000 ; 11 : 697-700.
76. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL et coll. : Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000 ; 18 : 243-5.
77. Skubitz KM : Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002 ; 20 : 693-9.
78. Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F et coll. : A prospective study of detorubicin in malignant mesothelioma. Cancer 1985 ; 56 : 2170-4.
79. Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ et coll. : Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992 ; 10 : 824-8.
80. Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M et coll. : Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 1992 ; 3 : 237-8.
81. Bretti S, Berruti A, Dogliotti L, Castagneto B, Bertulli R, Spadaro P et coll. : Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 1998 ; 84 : 558-61.
82. Magri MD, Veronesi A, Foladore S, De Giovanni D, Serra C, Crismancich F et coll. : Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE) - Mesothelioma Committee. Tumori 1991 ; 77 : 49-51.
83. Portalone L, Antilli A, Nunziati F, Crispino C, DeMarinis F, Friggeri L et coll. : Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. Tumori 2005 ; 91 : 15-8.
84. Steele JP, O'Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz MD et coll. : Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001 ; 12 : 497-9.
85. Kaukel E, Koschel G, Gatzemeyer U, Salewski E : A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 1990 ; 66 : 651-4.
86. Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R et coll. : Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 1986 ; 70 : 1029-30.
87. van Breukelen FJ, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A et coll. : Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991 ; 27 : 1627-9.
88. Hudis CA, Kelsen DP : Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest New Drugs 1992 ; 10 : 103-6.
89. Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A et coll. : Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2001 ; 24 : 143-7.
90. Halme M, Knuuttila A, Vehmas T, Tammilehto L, Mantyla M, Salo J et coll. : High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999 ; 80 : 1781-5.
91. Solheim OP, Saeter G, Finnanger AM, Stenwig AE : High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992 ; 65 : 956-60.
92. Kindler HL, Belani CP, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR : Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999 ; 86 : 1985-91.
93. Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM et coll. : Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 1994 ; 12 : 1436-42.
94. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C et coll. : Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003 ; 21 : 1556-61.
95. Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM et coll. : Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997 ; 79 : 2237-42.
96. Dhingra HM, Murphy WK, Winn RJ, Raber MN, Hong WK : Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma. Invest New Drugs 1991 ; 9 : 69-72.
97. Baas P, Ardizzoni A, Grossi F, Nackaerts K, Numico G, van Marck E et coll. : The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003 ; 39 : 353-7.
98. Otterson GA, Herndon JE, Watson D, Green MR, Kindler HL : Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer 2004 ; 44 : 251-9.
99. Kindler HL, Millard F, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR : Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001 ; 31 : 311-7.
100. van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A et coll. : A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999 ; 85 : 2577-82.
101. Cantwell BM, Earnshaw M, Harris AL. Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 1986 ; 70 : 1335-6.
102. Andersen MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H, Thylen A, Damgaard K et coll. : Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 1999 ; 24 : 39-43.
103. Icli F, Karaoguz H, Hasturk S, Kurt B, Akbulut H, Dincol D et coll. : Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 1996 ; 15 : 207-13.
104. Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992 ; 10 : 337-43.
105. Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD et coll. : A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 1992 ; 70 : 2547-51.
106. Talbot SM, Rankin C, Taub RN, Balcerzak SP, Jr., Bhoopalam N, Chapman RA et coll. : High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Cancer 2003 ; 98 : 331-6.
107. Altinbas M, Er O, Ozkan M, Coskun HS, Gulmez I, Ekici E et coll. : Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. Med Oncol 2004 ; 21 : 359-66.
108. Anderson H, Hasleton P, Michie AB, Johnson RJ, Thatcher N : 24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. Br J Dis Chest 1988 ; 82 : 64-9.
109. van Meerbeeck JP, Baas P, Debruyne C, Smit EF, van Klaveren RJ, Galdermans D et coll. : A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002 ; 38 : 779-83.
110. Falkson G, Vorobiof DA, Lerner HJ : A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 1983 ; 11 : 94-7.
111. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM : Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000 ; 18 : 3912-7.
112. Boutin C, Irisson M, Guerin JC, Roegel E, Paramelle B, Brambilla C et coll. : Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 1987 ; 71 : 205-6.
113. Kelsen D, Gralla R, Cheng E, Martini N : Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat Rep 1983 ; 67 : 821-2.
114. Cowan JD, Green S, Lucas J, Weick JK, Balcerzak SP, Rivkin SE et coll. : Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988 ; 6 : 247-8.
115. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma - a negative report. Cancer Chemother Pharmacol 1989 ; 24 : 133-4.
116. Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L, Splinter TA et coll. : Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997 ; 33 : 2211-5.
117. Tammilehto L, Maasilta P, Mantyla M, Salo J, Mattson K. Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 1994 ; 5 : 949-50.
118. Maksymiuk AW, Marschke RF, Jr., Tazelaar HD, Grill J, Nair S, Marks RS et coll. : Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998 ; 21 :610-3.
119. Kindler HL, Herndon JE, Zhang C, Green MR : Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2005 ; 48 : 423-8.
120. Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K et coll. : Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma-a feasibility study. Anticancer Drugs 2000 ; 11 : 257-61.
121. Vogelzang NJ, Herndon JE, Miller A, Strauss G, Clamon G, Stewart FM et coll. : High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999 ; 10 : 597-600.
122. van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, van Breukelen F et coll. : Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996 ; 74 : 961-3.
123. Vorobiof DA, Rapoport BL, Chasen MR, Abratt RP, Cronje N, Fourie L et coll. : Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 2002 ; 13 : 412-5.
124. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH : Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group. Clin Lung Cancer 2004 ; 6 : 43-7.
125. Astoul P, Picat-Joossen D, Viallat JR, Boutin C : Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998 ; 83 : 2099-104.
126. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E et coll. : Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 2001 ; 31 : 303-10.
127. Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM : A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma. Lung Cancer 2001 ; 31 : 67-72.
128. Ardizzoni A, Pennucci MC, Castagneto B, Mariani GL, Cinquegrana A, Magri D et coll. : Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994 ; 17 : 80-2.
129. Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BW: Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 1993 ; 13 : 9-12.
130. Boutin C, Viallat JR, van Zandwijk N, Douillard JT, Paillard JC, Guerin JC et coll. : Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991 ; 67 : 2033-7.
131. Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE : Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 1990 ; 10 : 531-4.
132. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Menard O et coll. : Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002 ; 121 : 1921-7.
133. Mendes R, O'Brien ME, Mitra A, Norton A, Gregory RK, Padhani AR et colll. : Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br J Cancer 2002 ; 86 : 336-41.
134. Bajorin D, Kelsen D, Mintzer DM : Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987 ; 71 : 857-8.
135. Eagan RT, Frytak S, Richardson RL, Creagan ET, Nichols WC : Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat Rep 1986 ; 70 : 429.
136. Falkson G, Vorobiof DA, Simson IW, Borden EC. Phase II trial of acivicin in malignant mesothelioma. Cancer Treat Rep 1987 ; 71 : 545-6.
137. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H et coll. : Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002 ; 20 : 274-81.